1. Monitoring the response of patients with cutaneous leishmaniasis to treatment with pentamidine isethionate by quantitative real-time PCR, and identification of Leishmania parasites not responding to therapy.
- Author
-
Mans DR, Kent AD, Hu RV, Lai A Fat EJ, Schoone GJ, Adams ER, Rood EJ, Alba S, Sabajo LO, Lai A Fat RF, de Vries HJ, and Schallig HD
- Subjects
- Adolescent, Adult, Aged, Antiprotozoal Agents therapeutic use, Female, Humans, Injections, Intramuscular, Leishmania drug effects, Leishmania growth & development, Leishmania braziliensis drug effects, Leishmania braziliensis growth & development, Leishmania braziliensis isolation & purification, Leishmania guyanensis drug effects, Leishmania guyanensis growth & development, Leishmania guyanensis isolation & purification, Leishmaniasis, Cutaneous epidemiology, Leishmaniasis, Cutaneous parasitology, Leishmaniasis, Cutaneous pathology, Male, Middle Aged, Parasite Load methods, Pentamidine administration & dosage, Prevalence, Skin drug effects, Skin pathology, Suriname epidemiology, Treatment Failure, Treatment Outcome, Young Adult, Leishmania isolation & purification, Leishmaniasis, Cutaneous drug therapy, Pentamidine pharmacology, Real-Time Polymerase Chain Reaction methods, Skin parasitology
- Abstract
Background: Leishmania (Viannia) guyanensis is believed to be the principal cause of cutaneous leishmaniasis (CL) in Suriname. This disease is treated with pentamidine isethionate (PI), but treatment failure has increasingly been reported., Aim: To evaluate PI for its clinical efficacy, to compare parasite load, and to assess the possibility of treatment failure due to other infecting Leishmania species., Methods: Parasite load of patients with CL was determined in skin biopsies using real-time quantitative PCR before treatment and 6 and 12 weeks after treatment. Clinical responses were evaluated at week 12 and compared with parasite load. In parallel, molecular species differentiation was performed., Results: L. (V.) guyanensis was the main infecting species in 129 of 143 patients (about 90%). PI treatment led to a significant decrease (P < 0.001) in parasite counts, and cured about 75% of these patients. Treatment failure was attributable to infections with Leishmania (Viannia) braziliensis, Leishmania (Leishmania) amazonensis and L. (V.) guyanensis (1/92, 1/92 and 22/92 evaluable cases, respectively). There was substantial agreement beyond chance between the parasite load at week 6 and the clinical outcome at week 12, as indicated by the κ value of 0.61., Conclusions: L. (V.) guyanensis is the main infecting species of CL in Suriname, followed by L. (V.) braziliensis and L. (L.) amazonensis. Furthermore, patient response to PI can be better anticipated based on the parasite load 6 weeks after the treatment rather than on parasite load before treatment., (© 2015 The Authors Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists, North American Clinical Dermatologic Society and St Johns Dermatological Society.)
- Published
- 2016
- Full Text
- View/download PDF